Chemical industry – Page 67
-
BusinessOn the innovation horizon
Bringing disruptive technology to market requires enhanced collaboration
-
OpinionHow do companies deal with political shifts?
Political instability hits small companies hardest
-
OpinionPreparing for the future of pharma
Dave Allen discusses how scenario planning helps to define uncertainty in pharma
-
-
BusinessUS government sued over merger crackdown
Business groups challenge Obama’s steps to limit tax inversions
-
BusinessRohm and Haas fined for safety violations
Fines relate to a trimethylaluminium explosion that injured four in January
-
ResearchMembrane reactor turns methane into aromatics
Catalytic technology could turn untapped hydrocarbons into valuable chemical feedstocks
-
BusinessAmgen and Advaxis partner on immuno-oncology
Deal covers rights to system for building cancer therapies specific to a patient’s own tumours
-
BusinessStandard antibody will bolster biopharma
New NIST reference material will help validate and compare analytical techniques
-
BusinessJob cuts at Takeda, Boehringer and Arena
Hundreds of positions eliminated as companies re-evaluate R&D
-
BusinessFibrant to quit US operations
Caprolactam supplier will shed hundreds of jobs, while operations in Europe and China continue
-
BusinessArkema boosts Bostik adhesives
New adhesives plant in Sweden and acquisition of Dutch firm Den Braven
-
BusinessCelgene and Jounce team up against cancer
Firms promise next-generation immuno-oncology as existing drugs rack up successes
-
BusinessFormer Lotte Chemical chief under fire
Ex-head of South Korean firm grilled by prosecutors over alleged fake accounting records
-
BusinessDuPont found liable in second of 3400 cancer cases
US jury awards over $5 million in claim linked to PFOA emitted by DuPont plant
-
BusinessJuno CAR-T trial suspended after patient deaths
Immunotherapy study restarted with amended pre-treatment protocol
-
OpinionTime for better incentives to keep drug costs low
Getting outraged at drug price hikes is all very well, but we need more constructive options
-
BusinessBrexit uncertainty ripples across regulation
What might leaving the EU mean for medicines regulation, the Unified Patent Court, and the UK’s participation in Reach?
-
BusinessAll part of the service
Simon Hirst, founder of contract research organisation Sygnature, is the 2016 Chemistry World entrepreneur of the year
-
BusinessNovartis partners with Xencor for cancer antibodies
Deal deepens Novartis’s focus on immuno-oncology